AstraZeneca to Cap Inhaler Costs at $35

AstraZeneca this week became the second company in recent weeks to announce it will cap the out-of-pocket costs that patients pay for its inhalers at $35. The cap is effective June 1 and will apply to the company’s entire range of inhaler products used to treat asthma and chronic obstructive pulmonary disease, including inhalers Symbicort, Breztri Aerosphere, and Airsupra. The cap will be applicable for patients who are uninsured or underinsured.

The post AstraZeneca to Cap Inhaler Costs at $35 appeared first on Pennsylvania Office of Rural Health.

Recommend0 recommendationsPublished in My Healthy Pennsylvania, Rural Health PA

Related Articles

9 Critical Questions on Medicaid and the Latino Healthcare Crisis

Latinos are uninsured more than two times the rate of their white peers. Given that Latinos are projected to grow to 29% of the population by 2050, this lack of healthcare coverage, including Medicaid, will continue to endanger the health of many more individuals, families, and the healthcare system. In honor of Minority Health Month, …
The post 9 Critical Questions on Medicaid and the Latino Healthcare Crisis appeared first on Salud America.

Many Latino Families Struggle with Child Care Cost, Access

Child care is crucial for Latino and all families, but some face issues with access and cost.   While many Latino households with low incomes used no-cost child care, those who paid out-of-pocket tended to face very high costs, according to a new research brief from the National Research Center on Hispanic Children and Families …
The post Many Latino Families Struggle with Child Care Cost, Access appeared first on Salud America.